Positive Outcomes from ONWARD Medical's Annual General Meeting
ONWARD Medical N.V. is at the forefront of neurotechnology, aiming to revolutionize therapies that restore movement and independence for individuals facing spinal cord injuries and movement disabilities. The recent Annual General Meeting of Shareholders (AGM) was a significant event that showcased the company's direction and shareholder support.
Resolutions Passed at the AGM
During the AGM, held in Amsterdam, shareholders expressed their confidence by approving all proposed resolutions. This unanimous support not only reflects the trust shareholders place in the company's leadership but also sets the stage for continued innovation and growth.
Future Innovations and Commitment to Spinal Rehabilitation
ONWARD Medical has dedicated years to scientific research and clinical development. This commitment has culminated in the introduction of ARC Therapy, a breakthrough treatment that has received acclaim from regulatory bodies, including ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The company is not only invested in current therapies but is also actively developing the investigational ARC-IM system, designed to integrate with brain-computer interfaces, presenting exciting future possibilities for patients.
Company Overview
Headquartered in the Netherlands, ONWARD Medical spans across Europe and offers a significant presence in the United States via its office in Boston, Massachusetts. The company’s dedication to pushing the boundaries of neurotechnology is evident through its successful ARC-EX System, which has gained regulatory clearance for commercial use in the U.S. With listings on Euronext Paris, Brussels, and Amsterdam, their commitment to accessibility and growth is commendable. The relevant tickers for investors include ONWD for Euronext and ONWRY for OTC trading in the U.S.
Partnering with the Community
ONWARD Medical is passionate about serving the spinal cord injury community. Their approach is collaborative, focusing on developing innovative solutions that make a tangible difference in patients' lives. Stakeholders interested in ongoing updates related to technologies and research studies can find comprehensive information through their official channels.
Contact Information
For more inquiries, whether related to media or investor relations, ONWARD Medical welcomes contact. The communications team can be reached through dedicated email addresses, ensuring that the right information reaches the necessary parties promptly.
Frequently Asked Questions
What were the outcomes of the recent ONWARD Medical AGM?
All proposed resolutions were approved unanimously by the shareholders during the AGM, showcasing strong support for the company's direction.
What is ARC Therapy, and why is it significant?
ARC Therapy is a groundbreaking treatment developed by ONWARD Medical intended to restore movement and independence for individuals with spinal cord injuries. It has received multiple Breakthrough Device Designations from the FDA, highlighting its potential impact.
What is the ARC-EX System?
The ARC-EX System is a commercially available device cleared by U.S. regulators that provides transcutaneous electrical spinal stimulation to aid recovery in individuals with chronic neurological deficits.
What are ONWARD Medical's future plans?
ONWARD is focused on advancing its investigational ARC-IM system and exploring brain-computer interfaces, demonstrating a commitment to innovation in treatment options for spinal cord injuries.
How can stakeholders stay informed about ONWARD Medical?
Stakeholders can learn about developments, therapies, and research updates by visiting ONWARD Medical’s official website and subscribing to their communication channels.
